Bristol-Myers Squibb Completes Amira Acquisition

Bristol-Myers Squibb said Thursday that it has completed its acquisition of privately held Amira Pharmaceuticals, a small-molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases.

The deal was originally announced on July 21, and has met all customary regulatory approval obligations. As a result of the acquisition, Amira has become a wholly-owned subsidiary of Bristol-Myers Squibb.

The acquisition of Amira Pharmaceuticals' fibrosis program, including the lead asset AM152, an orally available lysophosphatidic acid 1 receptor antagonist which has completed Phase I clinical studies and is now poised for Phase Iia proof-of-confidence studies for the treatment of idiopathic pulmonary fibrosis and systemic Sclerosis, or scleroderma, marks Bristol-Myers Squibb's entrance into fibrotic diseases. Bristol-Myers Squibb also has obtained Amira's preclinical autotaxin program, which may be useful in the treatment of neuropathic pain and cancer metastases.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.